<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is commonly transformed to a more aggressive diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In order to provide molecular characterization of this histological and clinical transformation, comparative genomic hybridization was applied to 23 follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 35 transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from a total of 30 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The results were also compared with our published findings in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Copy number changes were detected in 70% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and in 97% of transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the most common alterations were +18q21 (33%), +Xq25-26 (28%), +1q31-32 (23%), and -17p (23%), whereas transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> most frequently exhibited +Xq25-26 (36%), +12q15 (29%), +7pter-q22 (25%), +8q21 (21%), and -6q16-21(25%) </plain></SENT>
<SENT sid="5" pm="."><plain>Transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> showed significantly more alterations as compared to follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P=0.0001), and the alterations -6q16-21 and +7pter-q22 were only found in transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> but not in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P=0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>Alterations involving +13q22 were significantly less frequent, whereas -4q13-21 was more common in transformed as compared to de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (P=0.01 and P=0.02, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Clinical progression from follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> to transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> is on the genetic level associated with acquisition of increasing number of genomic copy number changes, with non-random involvement of specific target regions </plain></SENT>
<SENT sid="8" pm="."><plain>The findings support diverse genetic background between transformed and de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
</text></document>